Tag: HEA MTC PHA

DermaRite Industries Issues Voluntary Nationwide Recall of DermaKleen, Dermasarra, Kleenfoam, and Perigiene Products Due to Burkholderia cepacia Contamination

NORTH BERGEN, N.J., Aug. 8, 2025 /PRNewswire/ -- DermaRite Industries, LLC is voluntarily recalling individual lots of products in the table below due to...

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion

GUANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Sunshine Lake Pharma Co., Ltd. (06887.HK) announced that the company will officially list on the Hong Kong Stock...

Suppositories Market Worth $2.05 billion by 2030 with 4.7% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The global Suppositories Market, valued at US$1.56 billion in 2024 stood at US$1.63 billion in 2025 and...

New Force in Vaccine National Team: NHRI Spin-off ‘TaiU’ Completes US$2M Seed Round Led by MVL Seed Fund

TAIPEI, Aug. 1, 2025 /PRNewswire/ -- Taiwan Universe BioMedicine (TaiU), a startup spun off from the National Health Research Institutes (NHRI), today announced the completion...

EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia

-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, ‘EYLUXVI® (ALT-L9)’

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea®Upon approval, EYLUXVI® will...

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV)...

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohortsDarovasertib has received U.S. FDA Breakthrough Therapy Designation...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsHEA MTC PHA

Revenium Joins FinOps Foundation as Agentic AI Spend Outpaces the Tools Built to Govern It

TABAÑERO INTRODUCES FLORIDA-INSPIRED BBQ SAUCE COLLECTION FEATURING CLEAN INGREDIENTS AND BOLD FLAVOR

Share Buyback Transaction Details May 28 – June 3, 2026

Tag: HEA MTC PHA

DermaRite Industries Issues Voluntary Nationwide Recall of DermaKleen, Dermasarra, Kleenfoam, and Perigiene Products Due to Burkholderia cepacia Contamination

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion

Suppositories Market Worth $2.05 billion by 2030 with 4.7% CAGR | MarketsandMarkets™

New Force in Vaccine National Team: NHRI Spin-off ‘TaiU’ Completes US$2M Seed Round Led by MVL Seed Fund

EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, ‘EYLUXVI® (ALT-L9)’

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us